These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

790 related articles for article (PubMed ID: 27906698)

  • 61. Role of Biologics in Asthma.
    McGregor MC; Krings JG; Nair P; Castro M
    Am J Respir Crit Care Med; 2019 Feb; 199(4):433-445. PubMed ID: 30525902
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Evidence for the efficacy and safety of anti-interleukin-5 treatment in the management of refractory eosinophilic asthma.
    Hilvering B; Xue L; Pavord ID
    Ther Adv Respir Dis; 2015 Aug; 9(4):135-45. PubMed ID: 25900924
    [TBL] [Abstract][Full Text] [Related]  

  • 63. A review of anti-IgE monoclonal antibody (omalizumab) as add on therapy for severe allergic (IgE-mediated) asthma.
    D'Amato G; Salzillo A; Piccolo A; D'Amato M; Liccardi G
    Ther Clin Risk Manag; 2007 Aug; 3(4):613-9. PubMed ID: 18472983
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Promises and challenges of biologics for severe asthma.
    Tan R; Liew MF; Lim HF; Leung BP; Wong WSF
    Biochem Pharmacol; 2020 Sep; 179():114012. PubMed ID: 32389637
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Omalizumab in the treatment of severe asthma: efficacy and current problems.
    Pelaia G; Renda T; Romeo P; Busceti MT; Maselli R
    Ther Adv Respir Dis; 2008 Dec; 2(6):409-21. PubMed ID: 19124386
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Combination biologic therapy for severe persistent asthma.
    Ortega G; Tongchinsub P; Carr T
    Ann Allergy Asthma Immunol; 2019 Sep; 123(3):309-311. PubMed ID: 31251970
    [No Abstract]   [Full Text] [Related]  

  • 67. IgE-Related Chronic Diseases and Anti-IgE-Based Treatments.
    Navinés-Ferrer A; Serrano-Candelas E; Molina-Molina GJ; Martín M
    J Immunol Res; 2016; 2016():8163803. PubMed ID: 28097159
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Changes in total IgE plasma concentration measured at the third month during anti-IgE treatment predict future exacerbation rates in difficult-to-treat atopic asthma: a pilot study.
    Dal Negro RW; Guerriero M; Micheletto C; Tognella S; Visconti M
    J Asthma; 2011 Jun; 48(5):437-41. PubMed ID: 21599560
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The use of biological agents for the treatment of fungal asthma and allergic bronchopulmonary aspergillosis.
    Moss RB
    Ann N Y Acad Sci; 2012 Dec; 1272():49-57. PubMed ID: 23231714
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Anti-IgE in severe persistent allergic asthma.
    Fox H
    Respirology; 2007 Nov; 12 Suppl 3():S22-8; discussion S45-7. PubMed ID: 17956516
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Anti-IgE for chronic asthma in adults and children.
    Walker S; Monteil M; Phelan K; Lasserson TJ; Walters EH
    Cochrane Database Syst Rev; 2004; (3):CD003559. PubMed ID: 15266491
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Monoclonal Antibodies for the Management of Severe Asthma.
    Rubinsztajn R; Chazan R
    Adv Exp Med Biol; 2016; 935():35-42. PubMed ID: 27334730
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Predictors of response to therapy with omalizumab in patients with severe allergic asthma - a real life study.
    Kallieri M; Papaioannou AI; Papathanasiou E; Ntontsi P; Papiris S; Loukides S
    Postgrad Med; 2017 Aug; 129(6):598-604. PubMed ID: 28427296
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Anti IgE antibodies for the treatment of difficult asthma].
    Humbert M; Tonnel AB
    Rev Mal Respir; 2005 Dec; 22(6 Pt 1):983-90. PubMed ID: 16222222
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Biologicals in the Treatment of Bronchial Asthma].
    Haasler I; Taube C
    Pneumologie; 2017 Oct; 71(10):684-698. PubMed ID: 29017221
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Switching Biological Therapies in Severe Asthma.
    Scioscia G; Nolasco S; Campisi R; Quarato CMI; Caruso C; Pelaia C; Portacci A; Crimi C
    Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298514
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Asthma versus chronic obstructive pulmonary disease, the Dutch versus British hypothesis, and role of interleukin-5.
    Chambliss JM; Sur S; Tripple JW
    Curr Opin Allergy Clin Immunol; 2018 Feb; 18(1):26-31. PubMed ID: 29257776
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Novel Biological Therapies in Severe Asthma: Targeting the Right Trait.
    Varricchi G; Marone G; Spadaro G; Russo M; Granata F; Genovese A; Marone G
    Curr Med Chem; 2019; 26(16):2801-2822. PubMed ID: 29318959
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Unmet needs in the treatment of allergic asthma: potential role of novel biologic therapies.
    Storms WW
    J Manag Care Pharm; 2003; 9(6):534-43. PubMed ID: 14664661
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Mepolizumab for the treatment of severe eosinophilic asthma.
    Poulakos MN; Cargill SM; Waineo MF; Wolford AL
    Am J Health Syst Pharm; 2017 Jul; 74(13):963-969. PubMed ID: 28645995
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 40.